Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel R Altmann

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Trials|March 4, 2011
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Madhan Kolappan, Rickie Patani, et al.
The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.
Annals of Neurology|January 14, 2018
Deep gray matter volume loss drives disability worsening in multiple sclerosisArman Eshaghi, Ferran Prados, Wallace J Brownlee, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Trials|March 4, 2011
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Madhan Kolappan, Rickie Patani, et al.
The Lancet. Neurology|August 21, 2021
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a studyJ William L Brown, Nick G Cunniffe, Ferran Prados, et al.
Annals of Neurology|January 14, 2018
Deep gray matter volume loss drives disability worsening in multiple sclerosisArman Eshaghi, Ferran Prados, Wallace J Brownlee, et al.
Pageof 6